A syringe includes a plunger having a plunger tube with proximal and distal ends, a center tube with a center passage that extends within the plunger tube, and a balloon disposed over the center tube and sealingly fixed to at least one of the center tube and the plunger tube. The syringe also includes a barrel having a barrel tube having proximal and distal ends and an interior configured to accept a portion of the plunger, a tip fixedly coupled to the proximal end of the barrel tube, a post fixedly attached to the tip and extending within the barrel tube toward the distal end, the tip configured to partially extend into the center passage of the plunger, and a gas passage extending from a proximal end of the tip to the distal end of the post.

A stable pharmaceutical formulation comprising a protein of interest, sorbitol and polyethylene glycol (PEG). The sorbitol and protein is present in a molar ratio of 550 to 700 mole of sorbitol:1 mole of protein and the PEG to protein is present in the molar ratio of 2-50:1. The formulation optionally comprising buffer. The formulation in lyophilised form is stable for at least 4 years at 2-8° C. Also provided is a process for preparing the composition and a pharmaceutical kit comprising the same.

A system for injecting includes a cartridge body defining a proximal opening and a distal needle interface. The system also includes a plunger member defining a plunger interior and configured to be manually manipulated to insert a stopper member relative to the cartridge body. The plunger member includes a needle retention feature disposed in the plunger interior, an energy-storage member disposed in the plunger interior, and an energy-storage member latching member disposed in the plunger interior. The system further includes a needle hub assembly coupled to the distal needle interface of the cartridge body. The needle assembly includes a needle having a needle proximal end feature, a hub, and a needle latching member configured to couple the needle to the hub. The needle is retractable into plunger interior upon manipulation of the plunger member to actuate the energy-storage member latching member.

Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include applying AP magnetic fields having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to a target body area that includes the cancer or other rapidly-dividing cells.

An apparatus and associated methods of use for a controlled combination of reagents is disclosed. The apparatus includes a vessel 400, a vessel insert 220, and a cap element 200. The vessel 400 has a body portion 410 for receiving a biological sample. The vessel insert 220 receives at least one reagent therein. Preferably, the vessel insert 220 is received in a portion 420 of the vessel 400. The cap element 200 is attached to the vessel 400 to secure the vessel insert 220 in the vessel 400. During use, the vessel insert 220 is adapted to release its contents when the biological sample is introduced into the body portion 410 of the vessel 400 upon application of an intermixing force to the vessel insert 220. A variety of intermixing forces may be applied, depending upon the embodiment of the present invention and its associated methods of use.

An apparatus that includes a container portion and a coupler portion. The container and coupler are, in one embodiment, mated via an adapter that includes a one-way valve. The coupler includes a second one-way valve. In use, a fluid source, such as a vial, is connected to the coupler. An air source, such as a syringe is also connected to the coupler. Air from the syringe is introduced to the vial via the second one-way valve. The second one-way valve prevents fluid from the vial from being drawn into the syringe. Introduction of air from the syringe into the vial forces fluid from the vial into the container via the first one-way valve. The first one-way valve prevents the fluid from escaping the container.

Systems and method for destroying or inhibiting cancer cells and other rapidly-dividing cells include coupling an alternating polarity (AP) magnetic field generator to a target body area and applying an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.5-5 mT to the target body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer drug such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, or an angiogenesis inhibitor drug.

A system for mixing drug products and injecting includes a syringe body, proximal and distal stopper members disposed in the syringe body, a plunger member, and a needle hub assembly coupled to the distal needle interface of the syringe body. The proximal and distal stopper members form a proximal drug chamber between there between and a distal drug chamber between the distal stopper member and a distal end of the syringe body. The plunger member includes a needle retention feature, an energy-storage member, and an energy-storage member latching member all disposed in disposed in a plunger interior. First and second sizes of the respective proximal and distal drug chambers can be modified by movement of the proximal and distal stopper members relative to the syringe body. The needle is at least partially retractable into plunger interior upon manipulation of the plunger member relative to the syringe body.

A dosing device includes a rod element and a shell. The rod element has a stem with a longitudinal axis and a first thread arrangement. The shell has a second thread arrangement. The first thread arrangement of the rod element or the second thread arrangement of the shell includes a thread. The first thread arrangement of the rod element and the second thread arrangement of the shell engage. The rod element is movable along the longitudinal axis of its stem by rotating the shell and the rod element relative to each other causing the first thread arrangement of the rod element and the second thread arrangement of the shell to travel along each other. A dosage chamber is formed by moving the rod element along the longitudinal axis of its stem. The volume of the dosage chamber is varied by moving the rod element along the longitudinal axis of its stem. An inclination angle (α, β) of the thread varies along the thread. The dosing device according to the invention can allow for a precise and convenient dosing of a liquid out of a container. In particular, it can allow for efficiently dosing a comparably small volume out of a comparably large container.

A multi-mix infusion bag is provided. The multi-mix infusion bag includes a lower portion and an upper portion. The lower portion has a lower chamber and the upper portion includes a plurality of chambers. Each chamber is separated and contains a fluid agent. The multi-mix infusion bag is configured to transfer each fluid agent within each chamber of the upper portion into the lower chamber for mixing. The multi-mix infusion bag may include dispensing devices associated with each chamber, wherein the dispensing devices operate to transfer the fluid agents into the lower chamber for mixing.